Integral Diagnostics (ASX: IDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Integral Diagnostics Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $678.49 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 0
Earnings per share N/A
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Integral Diagnostics (ASX: IDX)
    Latest News

    Share Market News

    Integral Diagnostics share price on watch following FY 2020 earnings release

    The Integral Diagnostics Ltd (ASX: IDX) share price is on watch this morning following the release of its full year…

    Read more »

    Share Market News

    ASX small-cap sector rallies strongly during April

    The Australian small-cap sector performed particularly strongly during April. Here we examine what was behind this strong market rally.

    Read more »

    a woman
    Share Gainers

    The ASX small cap stocks enjoying a Bill Shorten boost

    A select group of medical stocks are defying the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) sell-off as they received a boost from…

    Read more »

    a woman
    Share Market News

    WAM Microcap Limited (ASX:WMI) declares special dividend, creates 31% returns

    WAM Microcap Limited (ASX:WMI) has reported its result for 30 June 2018.

    Read more »

    a woman
    ⏸️ Investing

    Is WAM Microcap Limited (ASX:WMI) the best LIC on the ASX?

    WAM Microcap Limited (ASX:WMI) could be the best LIC for the future.

    Read more »

    a woman
    ⏸️ Investing

    ALL ORDINARIES finishes lower Friday: 8 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished lower on Friday.

    Read more »

    a woman
    ⏸️ Investing

    Integral Diagnostics Ltd (ASX:IDX) announces profit upgrade and new acquisitions

    Integral Diagnostics Ltd (ASX:IDX) couples organic growth with an ambitious acquisition strategy.

    Read more »

    a woman
    ⏸️ Investing

    Top brokers name 3 ASX shares to buy today

    BHP Billiton Limited (ASX:BHP) shares are one of three that have been given buy ratings this week. Here's why...

    Read more »

    a woman
    ⏸️ Investing

    Here are 2 LICs with exciting futures

    These 2 LICs are generating strong returns.

    Read more »

    a woman
    ⏸️ Investing

    Top broker tipping this small cap to bounce back into favour after period of purgatory

    This small cap has been struggling recently and is underperforming its peers like Sonic Healthcare Limited (ASX:SHL) and Healthscope Ltd…

    Read more »

    a woman
    ⏸️ Investing

    Integral Diagnostics Ltd reports: Underlying NPAT up 22.7%

    Integral Diagnostics Ltd (ASX:IDX) reported a good set of numbers today.

    Read more »

    a woman
    ⏸️ Investing

    Why I think Integral Diagnostics Ltd could be a buy

    There’s been a bit of interest lately in Integral Diagnostics Ltd (ASX:IDX) lately. Here’s why…

    Read more »

    Frequently Asked Questions

    Yes, Integral Diagnostics historically pays two fully franked dividends a year.

    Integral Diagnostics generally pays its shareholder dividends in April and October.

    Integral Diagnostics Ltd listed on the ASX on 21 October 2015.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    30 Aug 2024 $0.0330 100.00% Final 03 Oct 2024
    29 Feb 2024 $0.0250 100.00% Interim 02 Apr 2024
    31 Aug 2023 $0.0350 100.00% Final 04 Oct 2023
    02 Mar 2023 $0.0250 100.00% Interim 04 Apr 2023
    01 Sep 2022 $0.0300 100.00% Final 05 Oct 2022
    01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
    02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
    01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
    28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
    28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
    30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
    01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
    31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
    31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 04 Oct 2017
    28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
    31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

    IDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Integral Diagnostics

    Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. 

    The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients. 

    The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.

    IDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 Nov 2024 $2.90 $0.00 0.00% 218,786 $2.89 $2.97 $2.89
    21 Nov 2024 $2.90 $-0.06 -2.03% 367,715 $2.92 $2.94 $2.85
    20 Nov 2024 $2.96 $-0.01 -0.34% 147,834 $3.00 $3.00 $2.92
    19 Nov 2024 $2.97 $0.00 0.00% 252,797 $3.04 $3.04 $2.97
    18 Nov 2024 $2.97 $-0.11 -3.57% 1,432,149 $3.06 $3.06 $2.96
    15 Nov 2024 $3.08 $0.06 1.99% 366,641 $3.02 $3.09 $3.02
    14 Nov 2024 $3.02 $-0.01 -0.33% 194,862 $3.07 $3.07 $3.00
    13 Nov 2024 $3.03 $-0.10 -3.19% 567,047 $3.12 $3.13 $3.01
    12 Nov 2024 $3.13 $0.01 0.32% 294,664 $3.10 $3.14 $3.10
    11 Nov 2024 $3.12 $0.06 1.96% 173,944 $3.08 $3.12 $3.05
    08 Nov 2024 $3.06 $0.00 0.00% 4,786,879 $3.09 $3.10 $3.05
    07 Nov 2024 $3.06 $0.06 2.00% 182,227 $3.03 $3.08 $3.02
    06 Nov 2024 $3.00 $0.05 1.69% 740,155 $2.96 $3.03 $2.94
    05 Nov 2024 $2.95 $-0.04 -1.34% 369,410 $2.98 $2.99 $2.95
    04 Nov 2024 $2.99 $0.00 0.00% 250,366 $2.99 $3.01 $2.94
    01 Nov 2024 $2.99 $-0.14 -4.47% 910,422 $3.14 $3.14 $2.96
    31 Oct 2024 $3.13 $0.03 0.97% 338,797 $3.10 $3.17 $3.10
    30 Oct 2024 $3.10 $0.00 0.00% 284,233 $3.10 $3.12 $3.08
    29 Oct 2024 $3.10 $-0.02 -0.64% 833,015 $3.11 $3.17 $3.10
    28 Oct 2024 $3.12 $-0.04 -1.27% 459,137 $3.17 $3.17 $3.11
    25 Oct 2024 $3.16 $0.03 0.96% 421,424 $3.13 $3.19 $3.13
    24 Oct 2024 $3.13 $0.02 0.64% 381,300 $3.10 $3.17 $3.06
    23 Oct 2024 $3.11 $-0.06 -1.89% 448,678 $3.18 $3.20 $3.10

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    07 Nov 2024 James Hall Buy 1,833 $5,425
    On-market trade.
    01 Nov 2024 Ian Kadish Issued 327,566 $979,422
    Issue of securities. 1,004,570 Rights
    16 Sep 2024 Ian Kadish Issued 29,072 $74,424
    Issue of securities. 677,004 Rights
    30 Aug 2024 Ian Kadish Issued 26,035 $67,691
    Conversion of securities.
    30 Aug 2024 Ian Kadish Exercise 26,035 $67,691
    Conversion of securities. 647,932 Rights,
    27 Aug 2024 Ian Kadish Expiry 184,616 $480,001
    As advised by the company. Lapsed, 673,967 Rights
    02 Apr 2024 James Hall Issued 1,719 $3,748
    Dividend Reinvestment Plan (DRP).
    02 Apr 2024 James Hall Issued 1,719 $3,748
    Dividend Reinvestment Plan (DRP). As per announcement on 04-04-2024
    01 Dec 2023 Andrew Fay Buy 15,000 $25,575
    On-market trade.
    01 Dec 2023 Ian Kadish Buy 20,000 $35,050
    On-market trade.
    30 Nov 2023 Ian Kadish Issued 248,970 $441,921
    Issue of securities. 858,583 - Rights
    30 Nov 2023 Ingrid Player Buy 35,000 $60,725
    On-market trade.
    30 Nov 2023 James Hall Buy 150,000 $258,225
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew James Fay Non-Executive Director Jul 2022
    Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. He is also Chair of the People and Culture Committee.
    Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
    Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Ms Ingrid Anne Player Non-Executive Director Aug 2023
    Ms Player has more than 20 years of experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australia's largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specializing in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She is Chair of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Mr James Tobias Hall Non-Executive Director Sep 2023
    Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra and advisory board member for Fujitsu Australia and New Zealand. He is a Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
    Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee. He is a Member of the Integral Clinical Leadership Committee.
    Mr John J Merity Interim Company Secretary Jun 2024
    -
    Ms Nikki Dalla Valle Company Secretary Dec 2023
    -
    Craig White Chief Financial Officer
    -
    Nikki Dalla Valle Company Secretary
    -
    John J Merity Interim Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Limited 42,793,666 18.29%
    J P Morgan Nominees Australia Pty Limited 39,158,798 16.74%
    HSBC Custody Nominees (Australia) Limited 38,626,662 16.51%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,678,603 2.00%
    Warbont Nominees Pty Ltd (Unpaid Entrepot A/c) 4,119,561 1.76%
    Washington H Soul Pattinson And Company Limited 4,087,223 1.75%
    HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) 3,906,185 1.67%
    Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 3,552,881 1.52%
    BNP Paribas Nominees Pty Ltd (Hub24 Custodial Serv Ltd) 3,407,901 1.46%
    New Imaging Pty Ltd (New Imaging A/c) 3,389,045 1.45%
    Lethean Holdings Pty Ltd (Howitt No 8 A/c) 2,944,760 1.26%
    Firbar Pty Ltd (The Howitt No 4 A/c) 2,357,230 1.01%
    J A Mullins Pty Ltd (James A Mullins Family A/c) 2,316,051 0.99%
    Masfen Securities Limited 2,250,000 0.96%
    Mittal Holdings Pty Ltd (Howitt No 12 A/c) 2,085,907 0.89%
    Mr Vincent Michael O'Sullivan (O'Sullivan A/c) 2,020,000 0.86%
    Wyndham Salter Pty Ltd (The Howitt No 10 A/c) 1,792,947 0.77%
    A & S French Pty Ltd (The AJ French Family A/c) 1,778,327 0.76%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 1,711,682 0.72%
    BNP Paribas Noms Pty Ltd 1,636,566 0.70%

    Profile

    since

    Note